In another study, PLX51107 slowed the growth of mouse BRAF V600E melanoma tumors by inducing the CD8+ T cell-mediated anti-tumor effects; moreover, PLX51107 proved to be an effective second-line therapy for CM tumors that harbored resistance to PD1/PDL1 checkpoint inhibition [264]. This evidence concerns the gene CD8A and neoplasm.